EP0656116A4 - Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections. - Google Patents

Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections.

Info

Publication number
EP0656116A4
EP0656116A4 EP93919871A EP93919871A EP0656116A4 EP 0656116 A4 EP0656116 A4 EP 0656116A4 EP 93919871 A EP93919871 A EP 93919871A EP 93919871 A EP93919871 A EP 93919871A EP 0656116 A4 EP0656116 A4 EP 0656116A4
Authority
EP
European Patent Office
Prior art keywords
individuals
methods
interferon therapy
hcv infections
monitoring effectiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93919871A
Other languages
German (de)
French (fr)
Other versions
EP0656116A1 (en
Inventor
Lieselotte Lennartz
Gerd Michel
Smriti U Methta
Suhas Taskar
John M Clemens
Larry T Mimms
Kurt H Chau
David S Vallari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP0656116A1 publication Critical patent/EP0656116A1/en
Publication of EP0656116A4 publication Critical patent/EP0656116A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93919871A 1992-08-21 1993-08-03 Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections. Withdrawn EP0656116A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93328392A 1992-08-21 1992-08-21
US933283 1992-08-21
PCT/US1993/007287 WO1994004922A1 (en) 1992-08-21 1993-08-03 Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections

Publications (2)

Publication Number Publication Date
EP0656116A1 EP0656116A1 (en) 1995-06-07
EP0656116A4 true EP0656116A4 (en) 1997-04-02

Family

ID=25463683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93919871A Withdrawn EP0656116A4 (en) 1992-08-21 1993-08-03 Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections.

Country Status (5)

Country Link
EP (1) EP0656116A4 (en)
JP (1) JPH08500673A (en)
AU (1) AU4996493A (en)
CA (1) CA2142872A1 (en)
WO (1) WO1994004922A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447650A (en) * 1993-10-06 1995-09-05 Allergan, Inc. Composition for preventing the accumulation of inorganic deposits on contact lenses
JPH11506199A (en) * 1995-06-07 1999-06-02 アボツト・ラボラトリーズ IgG / IgM ratio to quantify the efficacy of interferon treatment in individuals infected with HCV
EP1682894B1 (en) * 2003-11-12 2011-01-05 HBV Theranostica AB Methods relating to hepatitis b infection
GB0326416D0 (en) 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DD DOUGLAS ET AL: "Chronic hepatitis C response to interferon therapy: comparison of ALT normalization with anti-HCV IgM, anti-HCV IgG and HCV-RNA polymerase chain reaction.", HEPATOLOGY, vol. 14, no. 4, 1 October 1991 (1991-10-01), CHICAGO IL USA, pages 74A., XP000614912 *
S. BRILLANTI ET AL.: "Significance of IgM antibody to Hepatitis C virus in patients with chronic hepatitis C.", HEPATOLOGY, vol. 15, no. 6, 1 June 1992 (1992-06-01), CHICAGO IL USA, pages 998 - 1001, XP000614911 *
See also references of WO9404922A1 *

Also Published As

Publication number Publication date
EP0656116A1 (en) 1995-06-07
AU4996493A (en) 1994-03-15
JPH08500673A (en) 1996-01-23
WO1994004922A1 (en) 1994-03-03
CA2142872A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0658116A4 (en) Methods useful in endotoxin prophylaxis and therapy.
EP0595783A3 (en) Ultrasonic treatment system
ZA926986B (en) Exhaust treatment system
HUT70311A (en) Method for the preparation and purification of alpha - interferon
KR100321237B1 (en) Laminate and use of the same
GB9323044D0 (en) In or relating to the treatment of effluents
IL106037A0 (en) Therapeutic and diagnostic methods based on neurotrophin-4-expression
EP0656791A4 (en) Therapeutic compositions and methods using pqq.
ZA935575B (en) Therapeutic agent and its use.
GB9304746D0 (en) Treatment of viral infections
GB9203039D0 (en) Treatment
EP0656116A4 (en) Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections.
GB9211736D0 (en) Allergic treatment
GB9419692D0 (en) Treatment of herpes infections
EP0655919A4 (en) Treatment of human viral infections.
ZW5790A1 (en) Interferon for the use in the prevention or treatment of swine pneumonia or related bacterial diseases
SG47098A1 (en) Diamines in the treatment of arrhythmia
GB9111885D0 (en) Nerve growth factor for use in the prevention and treatment of viral infections
GB9315959D0 (en) Footrests
EP0603615A3 (en) Process of purification and enrichment of the Rubella Virus.
IL108749A0 (en) Selective treatment of enteroviral-caused infections in humans
ZA932458B (en) Naphtoquinones and their use.
ZA939794B (en) Curved shatterproof glass laminate and method of forming the laminate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI

RHK1 Main classification (correction)

Ipc: G01N 33/576

A4 Supplementary search report drawn up and despatched

Effective date: 19970214

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI

17Q First examination report despatched

Effective date: 19990319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990730